4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.40 Average Target Price from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $30.40.

FDMT has been the subject of several research reports. Roth Capital dropped their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Chardan Capital reiterated a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Saturday, August 30th.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock traded down $0.26 on Monday, hitting $6.81. 517,375 shares of the company's stock were exchanged, compared to its average volume of 617,578. The company has a 50 day moving average of $5.70 and a 200 day moving average of $4.35. The stock has a market cap of $318.03 million, a P/E ratio of -1.93 and a beta of 2.86. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $17.41.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%. Sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently added to or reduced their stakes in FDMT. BVF Inc. IL lifted its holdings in 4D Molecular Therapeutics by 70.8% during the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock worth $14,733,000 after buying an additional 1,890,647 shares during the period. Millennium Management LLC increased its stake in shares of 4D Molecular Therapeutics by 1,607.1% in the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock valued at $7,913,000 after acquiring an additional 1,337,497 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of 4D Molecular Therapeutics by 33,131.8% during the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock valued at $4,038,000 after acquiring an additional 1,246,419 shares during the period. Cubist Systematic Strategies LLC boosted its stake in 4D Molecular Therapeutics by 2,084.5% during the fourth quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company's stock worth $2,500,000 after acquiring an additional 428,285 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in 4D Molecular Therapeutics by 1,103.4% during the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company's stock worth $1,290,000 after acquiring an additional 367,317 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.